Physician profile
Robert A Quint
NPI 1649348350
$5,975.21
in general payments reported to CMS, 2019-2025
28 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,484 · 2020: $522 · 2021: $574 · 2022: $869 · 2023: $1,149 · 2024: $809 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.41 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $586.86 | 2020-2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $537.39 | 2022-2025 | Verquvo, Capvaxive |
| Shockwave Medical, INC | $524.09 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $490.92 | 2019-2025 | |
| Pfizer INC. | $410.64 | 2019-2025 | |
| Philips North America LLC | $400.88 | 2019-2021 | |
| Amgen INC. | $355.05 | 2020-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $303.96 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $287.71 | 2019-2020 | |
| Biotronik INC. | $276.49 | 2019-2020 | |
| Novo Nordisk INC | $221.81 | 2021-2023 | |
| Esperion Therapeutics, INC. | $174.83 | 2020-2024 | Nexletol, Nexlizet |
| Heartflow, INC. | $144.26 | 2025 | |
| Sanofi-Aventis U.S. LLC | $142.60 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.12 | 2023-2024 | Lifevest |
| Lundbeck LLC | $125.00 | 2019 | |
| Portola Pharmaceuticals, LLC | $124.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $113.64 | 2022 | |
| Abbott Laboratories | $54.81 | 2020-2024 | Amplatzer Amulet |
| Astrazeneca Pharmaceuticals LP | $40.16 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.06 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $33.46 | 2019-2022 | |
| Glaxosmithkline, LLC. | $27.55 | 2025 | Shingrix |
| Baxter Healthcare | $25.75 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $25.74 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $21.38 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $20.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Quint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.